Mellitus
Christopher de Souza is a Director at Broadview Ventures in Boston. He started his pharmaceutical career at Novartis as a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances. After Novartis, Christopher was VP of Business Development at SkyePharma US and also founded a business development consulting practice.
Dr. de Souza received an MBA from Rutgers University and a Ph.D. in physiology from Louisiana State University. He completed his post-doctoral training at “The Upjohn Company” and the Joslin Diabetes Center/Harvard Medical School.
This person is not in the org chart
Mellitus
Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk and as a clinical trial test for pharmaceutical development. Mellitus' lead product candidate is a test for Gestational Diabetes Mellitus (GDM).